Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BOPA 2018 | Regulatory approval of CPX-351 for secondary AML

Charles Craddock, CBE, FRCP(UK), FRCPath, DPhil, of the University of Birmingham, Birmingham, UK, notes a significant survival advantage for patients with secondary acute myeloid leukemia (AML) receiving liposomal CPX-351 (liposomal formulation of cytarabine and daunorubicin) vs. standard 7+3 regimens. Speaking from the British Oncology Pharmacy Association (BOPA) Annual Symposium 2018, held in Birmingham, UK, Prof. Craddock also poses questions regarding treatment options for high-risk patients with AML who exhibit differences in measurable residual disease (MRD) levels, considering the improved transplant outcomes for patients who achieved lower MRD levels following CPX-351 treatment.